コンテンツへスキップ
Merck
  • Doxorubicin and 5-fluorouracil induced accumulation and transcriptional activity of p53 are independent of the phosphorylation at serine 15 in MCF-7 breast cancer cells.

Doxorubicin and 5-fluorouracil induced accumulation and transcriptional activity of p53 are independent of the phosphorylation at serine 15 in MCF-7 breast cancer cells.

Cancer biology & therapy (2014-05-08)
Matthew T Balmer, Ryan D Katz, Si Liao, James S Goodwine, Susannah Gal
要旨

The chemotherapeutic agents doxorubicin (dox) or 5-fluorouracil (5FU) are used to treat cancer cells as they cause irreparable DNA damage, inducing these aberrant cells to undergo cell death. The mediator of this process is presumed to be in part the tumor suppressor p53 which regulates genes involved in DNA repair and cell death. When MCF-7 breast cancer cells are treated with these drugs, we observed that the level of p53 and the p53 negative regulator, Mdm2, increased, as seen by others. But contrary to some reports, we observed minimal phosphorylation of p53 at serine 15 in MCF-7 cells after drug treatment. Interestingly, we determined that there was differential regulation of the kinases ATM and Chk2 with the drug treatments, likely the cause for the lack of phosphorylation of p53. We found a dramatic drop in p53 DNA binding affinity for p21 and other gene response elements (RE) after drug treatment. To determine if the p53 that accumulated in the drug treated cells was functionally active, we monitored changes in the protein products of two p53-regulated genes following drug treatment with and without the addition of a p53-specific siRNA. In response to 5FU, both p21 and Mdm2 proteins increased and that increase was alleviated if a p53-specific siRNA was added. This effect was not seen with the addition of dox. Thus, the phosphorylation at serine 15 is not necessary for the functional activation of this transcription factor. We propose a new model for the regulation of p53, Mdm2, and MdmX after drug treatment.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ジメチルスルホキシド, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
ジメチルスルホキシド, ACS reagent, ≥99.9%
Sigma-Aldrich
ジメチルスルホキシド, for molecular biology
Sigma-Aldrich
ジメチルスルホキシド, suitable for HPLC, ≥99.7%
Sigma-Aldrich
ジメチルスルホキシド, sterile-filtered, BioPerformance Certified, meets EP, USP testing specifications, suitable for hybridoma
Sigma-Aldrich
ジメチルスルホキシド, ReagentPlus®, ≥99.5%
Sigma-Aldrich
ジメチルスルホキシド, ≥99.5% (GC), suitable for plant cell culture
Sigma-Aldrich
ジメチルスルホキシド, puriss. p.a., ACS reagent, ≥99.9% (GC)
Sigma-Aldrich
モノクロナール抗β-アクチン マウス宿主抗体, clone AC-15, ascites fluid
Sigma-Aldrich
ドキソルビシン 塩酸塩, 98.0-102.0% (HPLC)
Sigma-Aldrich
5-フルオロウラシル, ≥99% (HPLC), powder
Sigma-Aldrich
ヒトインスリン, recombinant, expressed in yeast, γ-irradiated, suitable for cell culture
Sigma-Aldrich
ジメチルスルホキシド, BioUltra, for molecular biology, ≥99.5% (GC)
Sigma-Aldrich
ジメチルスルホキシド, PCR Reagent
Sigma-Aldrich
ジメチルスルホキシド, puriss. p.a., dried, ≤0.02% water
Sigma-Aldrich
Z-Leu-Leu-Leu-al, ≥90% (HPLC)
Sigma-Aldrich
ジメチルスルホキシド, anhydrous, ≥99.9%
Roche
ストレプトアビジン磁性粒子, suspension
USP
ジメチルスルホキシド, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Fluorouracil, meets USP testing specifications
USP
5-フルオロウラシル, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
ジメチルスルホキシド, meets EP testing specifications, meets USP testing specifications
Sigma-Aldrich
Human p53 ELISA Kit, for serum, plasma, cell culture supernatant and urine
Sigma-Aldrich
Anti-p53 (Ab-6) (Pantropic) Mouse mAb (DO-1), liquid, clone DO-1, Calbiochem®
Sigma-Aldrich
ジメチルスルホキシド, ≥99.5%
Sigma-Aldrich
ジメチルスルホキシド, JIS special grade, ≥99.0%
Sigma-Aldrich
ジメチルスルホキシド 溶液, 50 wt. % in H2O
Supelco
ジメチルスルホキシド, analytical standard
Sigma-Aldrich
ジメチルスルホキシド, Vetec, reagent grade, 99%
Sigma-Aldrich
ジメチルスルホキシド, suitable for HPLC